Research in the field of pharmacogenetics and pharmacogenomics goes far beyond drugs currently in use in the clinic.
Many promising drugs for the treatment of a disease fail in the final stages for approval due mainly to lack of effectiveness or adverse effects. Human genetics may support the development of new therapies and may provide new knowledge about its early safety in drug development. The inclusion of genetics knowledge during the early stages of drug development may allow the stratification of patients and the identification of subgroups of patients who are more likely to react.
The Genomic Medicine Grouphas chosen the integration of this discipline in the early development of drugs, which is favoured by the proximity between the facilities of Innopharma platform and the area of pharmacogenetics.